Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs ALA-SCALP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Topical application of a 5% solution to the scalp twice daily.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
Not characterized; systemic levels are negligible after topical administration.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
No dose adjustment required. Topical use with minimal systemic absorption.
No dose adjustment required for renal impairment.
No dose adjustment required. Topical use with minimal systemic absorption.
No dose adjustment required for hepatic impairment.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Safety and efficacy in pediatric patients have not been established.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
No FDA black box warning.
No FDA black box warning.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
No known food interactions with topical Aclovate.
No known food interactions. No dietary restrictions required.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs ALA-SCALP, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and ALA-SCALP depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and ALA-SCALP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.